Immunotherapy

• Pembrolizumab Achieves Survival Improvements Across PD-L1 Status In KEYNOTE-407 Trial
• PACIFIC Update Demonstrates Durvalumab OS Benefit For Stage III Inoperable NSCLC
• Nivolumab, Nivolumab Plus Ipilimumab ‘Supported’ For Western Refractory Oesophagogastric Cancer Patients
• Pharmacotherapy and drug interactions
• Baseline Corticosteroid Use May Diminish NSCLC Immunotherapy Efficacy
• Radiomic Signature Predicts Response To PD-1 Pathway Blockade
• Diverse Delayed Skin Reactions To PD-1 Inhibitor Therapy Revealed
• Overall Survival Remains ‘Gold Standard’ For PD-1 Inhibitor Trial Endpoints
• Active8 Shows No ITT Survival Benefit For Motolimod Use In Recurrent, Metastatic SCCHN
• Highlights of Posters at ESMO GI on colorectal cancer
• Keynote Lecture: Understanding relevant immune mechanisms in GI oncology
• Metastatic gastric cancer: Where are we with check-point inhibitors in gastric cancer?
• Management of melanoma with immunotherapy and targeted treatment
• Adjuvant MAGE-A3 Vaccine Fails To Improve Stage III Melanoma Disease-Free Survival
• Immune check point inhibitors: Immunologic background, indications and innovations
• ASCO 2018: Immune Checkpoint Inhibitor Updates Reported For Merkel Cell Carcinoma
• Perspectives from ASCO 2018: Early breast cancer, the PERSEPHONE study
• Perspectives from ASCO 2018: Immunotherapy research in oncogene driven NSCLC, The ImmunoTarget and early combination study
• Perspectives from ASCO 2018: Advances in Gastric and Oesophageal Cancers, the KEYNOTE-061 trial
• Perspectives from ASCO 2018: Tumour mutation burden, a novel biomarker
• Perspectives from ASCO 2018: Novelties in Head and Neck cancers
• Perspectives from ASCO 2018: Highlights in multiple myeloma, the A.R.R.O.W. and OPTIMISMM trials
• ESMO videos: Perspectives from ASCO 2018
• ASCO 2018: TOPACIO/KEYNOTE-162 Findings ‘Promising’ For Metastatic TNBC and Recurrent Ovarian Cancer

• « Previous
• 1
• 2
• ...
• 70
• Next »